Medicare Proposes Updates to Kidney Dialysis Payments and Quality for 2027

You might care about this because the Centers for Medicare & Medicaid Services (CMS) has proposed new rules that will change how Medicare pays for kidney dialysis services and how dialysis facilities are expected to meet quality standards in 2027. This proposal focuses on three main areas: the payment system for individuals with End-Stage Renal Disease (ESRD), payments for those with Acute Kidney Injury (AKI), and the quality incentive program for dialysis facilities. For ESRD, CMS plans to update the payment rates, revise how it calculates costs, and adjust certain payments, including those for phosphate binders and for pediatric patients. For AKI, the payment rate will also be updated, as it is tied to the ESRD rates. The quality program, known as the ESRD Quality Incentive Program, will see changes to its performance measures. This includes replacing an old measure, updating another, and removing two measures related to medication reconciliation and COVID-19 vaccination coverage for staff. CMS is also seeking public feedback on ways to improve dialysis care, especially regarding increasing home dialysis options, palliative care, and alternative dialysis schedules. These proposed changes aim to improve the quality of care and ensure fair payments for dialysis services across the country. The public has until August 24, 2026, to submit comments on this proposed rule. What makes this document particularly interesting is its direct impact on the financial landscape for dialysis providers and the care standards for kidney patients. The proposed increase in the ESRD Prospective Payment System base rate to $299.55 for 2027, up from $281.71, is a significant financial adjustment. Importantly, this new rate would specifically include payment for phosphate binders, which are medicines many dialysis patients need. This integration could streamline how these common medications are covered and accessed. The changes within the ESRD Quality Incentive Program also highlight evolving priorities in patient care. Replacing the Hypercalcemia reporting measure with a Hyperphosphatemia clinical measure shows a shift towards addressing a different, yet critical, mineral imbalance in dialysis patients. Updating the infection measure reinforces the ongoing focus on patient safety. Furthermore, removing the COVID-19 vaccination measure reflects a possible recalibration of public health priorities within the program. The requests for information on home dialysis and palliative care are forward-looking. They signal CMS's intention to explore new policies that could change how dialysis is delivered, potentially making it more patient-centered and accessible outside traditional clinic settings. These explorations could lead to major shifts in how kidney care is managed in the future. Several groups would find this legal document highly relevant. First and foremost, dialysis patients and their families should be interested, as these changes could affect the quality of care they receive and the services available to them. This is especially true for those with ESRD and AKI. Second, dialysis facilities and providers, including freestanding clinics and hospital-based units, will be directly impacted by the proposed payment rate updates and changes to the quality incentive program. Their operational budgets and reporting requirements will be affected. Third, nephrologists, nurses, and other healthcare professionals who treat kidney disease patients need to understand these updates to ensure compliance and provide appropriate care. Fourth, pharmaceutical companies that produce medications like phosphate binders will be interested in how their products are incorporated into the payment system. Fifth, organizations involved in healthcare policy, research, and patient advocacy will find this document important for understanding the direction of Medicare's kidney care initiatives. Finally, anyone interested in the economics of healthcare or the future of chronic disease management will find valuable insights into how federal policy shapes patient care.